Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study

Journal of the American Society of Nephrology

Volumn 16, Issue 8, 2005, Pages 2456-2461

  Fliser, Danilo ^a   Kronenberg, Florian ^b   Kielstein, Jan T ^a   Morath, Christian ^c   Bode Böger, Stefanie M ^d   Haller, Hermann ^a   Ritz, Eberhard ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PARATHYROID HORMONE;

ADULT; ARTICLE; BIOAVAILABILITY; CHRONIC KIDNEY DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HYPOTHESIS; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; REGRESSION ANALYSIS;

EID: 27444444747     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005020179     Document Type: Article

References (35)

1. Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90: 278-281, 1992
2. Fujihara CK, De Nucci G, Zatz R: Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy. J Am Soc Nephrol 5: 1498-1507, 1995
3. Benigni A, Zoja C, Noris M, Corna D, Benedetti G, Bruzzi I, Todeschini M, Remuzzi G: Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. Am J Kidney Dis 33: 746-753, 1999
4. Kang DH, Nakagawa T, Feng L, Johnson RJ: Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 161: 239-248, 2002
5. Erdely A, Wagner L, Muller V, Szabo A, Baylis C: Protection of Wistar Furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase. J Am Soc Nephrol 14: 2526-2533, 2003
6. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, Huang PL, Isner JM: Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101: 2567-2578, 1998
7. Shao J, Miyata T, Sogabe H, Yamada K, Hanafusa N, Okuda T, Gordon KL, Kurosawa K, Fujita T, Johnson J, Nangaku M: A protective role of nitric oxide in a model of thrombotic microangiopathy in rats. J Am Soc Nephrol 12: 2088-2097, 2001
8. Ostendorf T, Van Roeyen C, Westenfeld R, Gawlik A, Kitahara M, De Heer E, Kerjaschki D, Floege J, Ketteler M: Inducible nitric oxide synthase-derived nitric oxide promotes glomerular angiogenesis via upregulation of vascular endothelial growth factor receptors. J Am Soc Nephrol 15: 2307-2319, 2004
9. Vallance P: Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 358: 2096-2097, 2001
10. Fliser D, Kielstein JT, Bode-Boger SM, Haller H: Asymmetric dimethylarginine (ADMA): A cardiovascular risk factor in patients with renal disease? Kidney Int 63[Suppl 84]: S37-S40, 2003
11. Cooke JP: Asymmetrical dimethylarginine: The Uber marker? Circulation 109: 1813-1818, 2004
12. Wagner L, Riggleman A, Erdely A, Couser W, Baylis C: Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis. Kidney Int 62: 532-536, 2002
13. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13: 170-176, 2002
14. Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M, Ogawa T, Vallance P, Wilcox CS: Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 52: 1593-1601, 1997
15. Nijveldt RJ, Van Leeuwen PA, Van Guldener C, Stehouwer CD, Rauwerda JA, Teerlink T: Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant 17: 1999-2002, 2002
16. Kronenberg F, Kuen E, Ritz E, Junker R, König P, Kraatz G, Lhotta K, Mann JFE, Müller GA, Neyer U, Riegel W, Riegler P, Schwenger V, Von Eckardstein A: Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 11: 105-115, 2000
17. Kronenberg F, Kuen E, Ritz E, Konig P, Kraatz G, Lhotta K, Mann JF, Muller GA, Neyer U, Riegel W, Riegler P, Schwenger V, von Eckardstein A: Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. J Am Soc Nephrol 13: 461-469, 2002
18. Gaspari F, Perico N, Matalone M, Signorini O, Azzollini N, Mister M, Remuzzi G: Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. J Am Soc Nephrol 9: 310-313, 1998
19. Martens-Lobenhoffer J, Bode-Boger SM: Simultaneous detection of arginine, asymmetric dimethylarginine, symmetric dimethylarginine and citrulline in human plasma and urine applying liquid chromatography-mass spectrometry with very straightforward sample preparation. J Chromatogr B Biomed Sci Appl 798: 231-239, 2003
20. Lindner W, Wainer IW: Requirements for initial assay validation and publication in J. Chromatography B. J Chromatogr B Biomed Sci Appl 707: 1-2, 1998
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985
22. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Hoeper MM, Frolich JC, Haller H, Fliser D: Cardiovascular effects of systemic NO synthase inhibition with asymmetric dimethylarginine in humans. Circulation 109: 172-177, 2004
23. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23: 1455-1459, 2003
24. Kielstein JT, Simmel S, Bode-Boger SM, Roth HJ, Schmidt-Gayk H, Haller H, Fliser D: Subpressor dose asymmetric dimethylarginine (ADMA) modulates renal function in humans. Kidney Blood Press Res 27: 143-147, 2004
25. Kielstein JT, Bode-Boger SM, Frolich JC, Ritz E, Haller H, Fliser D: Asymmetric dimethylarginine (ADMA), renal perfusion and blood pressure in elderly subjects. Circulation 107: 1891-1895, 2003
26. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992
27. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E: Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 11: 2449-2452, 1996
28. Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM, Frolich JC: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10: 594-600, 1999
29. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358: 2113-2117, 2001
30. Xiao S, Wagner L, Schmidt RJ, Baylis C: Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int 59: 1466-1472, 2001
31. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Boger R; CREED Investigators: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 13: 490-496, 2002
32. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, Tsao PS, Kimoto M, Vallance P, Patterson AJ, Cooke JP: Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: Genetic and physiological evidence. Circulation 108: 3042-3047, 2003
33. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H: Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 16: 1135-1140, 2005
34. Ritz E, Dikow R, Zeier M: Compelling drug indications in diabetic and nondiabetic nephropathy. Curr Hypertens Rep 6: 293-299, 2004
35. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334: 939-945, 1996